

LivaNova


Health innovation that matters

LivaNova Investor Day

Jason Richey

General Manager,
Neuromodulation &
President, North America

September 14, 2017



Safe Harbor Statement

Certain statements in this presentation, other than purely historical information, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements include, but are not limited to, LivaNova’s plans, objectives, strategies, financial performance and outlook, trends, the amount and timing of future cash distributions, prospects or future events and involve known and unknown risks that are difficult to predict. As a result, our actual financial results, performance, achievements or prospects may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” “believe,” “will,” “should,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “forecast,” “foresee” or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based on estimates and assumptions that, while considered reasonable by LivaNova and its management based on their knowledge and understanding of the business and industry, are inherently uncertain. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements. There are a number of risks, uncertainties and other important factors, many of which are beyond our control, that could cause our actual results to differ materially from the forward-looking statements contained in this press release, including those described in the “Risk Factors” section of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, the Registration Statement on Form S-4 and other documents filed from time to time with the United States Securities and Exchange Commission by LivaNova.

The Company does not undertake or assume any obligation to update publicly any of the forward-looking statements in this presentation to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. We caution you not to place undue reliance on any forward-looking statements, which are made only as of the date of this presentation.

We are the market leader in Vagus Nerve Stimulation (VNS) Therapy[®]

EPILEPSY



Significant growth opportunity

DEPRESSION



Unmet global need

CUSTOMERS

Neurologists
Epileptologists
Psychiatrists
Neurosurgeons
Patients

DISEASE STATE


Drug-resistant epilepsy
(DRE)
Treatment-resistant
depression
(TRD)

MARKET

Large underpenetrated
markets with opportunity
for organic and inorganic
growth

Neuromodulation is a large and growing market

Neuromodulation (NM) Market



Technology advancements

- Miniaturization
- Battery longevity
- Enhanced safety
- Improved efficacy




Growing number of indications

- Epilepsy
- Chronic pain
- Obesity
- Movement disorders
- Psychiatric disorders
- Cardiovascular disorders
- Gastrointestinal disorders
- Genitourinary disorders




Patient awareness and physician acceptance

- Patients largely influence treatment plans
- Direct-to-consumer marketing
- Clinical data
- Removing barriers



~35% of patients need treatment beyond medication

Significant growth opportunity remains



Growing through innovation and patient awareness

Remove barriers

MRI (U.S. and OUS) and
pediatric labeling expansions (U.S.)

Innovation

Maintain new product cadence
every 12-24 months

International growth
opportunities

Strategic targeting of key markets

Patient awareness

Direct-to-consumer marketing
and clinical studies

Universal
platform

Supports cost reduction and
inorganic growth through M&A

Unlocking potential via labeling expansions

Pediatric

FDA expanded VNS Therapy access to patients as young as age 4 (2017)

OUS CE Mark approval with no age restrictions (1994)

Clinical data proves early adjunctive use yields better results

Patients having seizures for <10 years respond better to VNS Therapy

VNS Therapy has shown to help children reach important developmental milestones

MRI

FDA approval and CE Mark for expanded MRI labeling (2017)


VNS Therapy continues to be the only implantable epilepsy device approved by FDA for MRI scans

Patients now have access to 90% of MRI scans routinely performed on people with epilepsy

Reduces average distance to MRI centers significantly

Developing customer-centric innovation

Providing ease of use, better patient care, cost effectiveness



SenTiva™ innovations

- Senses bradycardia and tachycardia
- Monitors patient sleeping position
- Provides scheduled dosing
- Next-generation programmer
- New user interface on tablet
- Wireless wand

Future generations

- Auto gain control – minimal device positioning by physician
- Microburst – new vagus nerve stimulation method for different area of brain
- Wearable technology
- Patient apps and portals
- Cloud-based capabilities
- Data and analytics tools
- Comprehensive disease management

Targeting international markets


More than 100K global patients treated

OUS

- Focused team with regional marketing
- Key markets: UK, Germany, Nordics, France, Japan

U.S.

- Increase sales force
- Enhance R&D teams




Clinical studies to further support adoption

Our customers rely on data

PATIENT REGISTRY	EARLY ADJUNCTIVE USE STUDY
<ul style="list-style-type: none">• Goes live in parallel with SenTiva launch• Tracks seizure activity and overall patient quality of life• Periodic data reviews• Health economics data	<ul style="list-style-type: none">• Prospective multi-center study• Patients 4+ years• VNS as adjunctive therapy• Early use of VNS:<ul style="list-style-type: none">• Reduces seizures• Reduces recovery time• Improves cognitive results• Enhances performance development
Multi-year Registry	Multi-year Study
Launches 2017	Launches 2018

Universal platform: foundation for additional indications





Depression affects patients in the prime of their life and burdens families and society

Depression

- 300M+ patients globally
- Median age of onset: 25 years
- Fewer than half of patients receive treatment
- Leading cause of disability and major burden

Treatment-Resistant Depression (TRD)

- ~10-30% of patients with depression
- Median age 40+ after 2+ unsuccessful treatments (medications, psychotherapy, electroconvulsive therapy)
- More relapse, less remission, more side effects

VNS Therapy as an adjunctive treatment

- 800 TRD patients with 4+ unsuccessful prior treatments for 5 years
- 40.9% responded with treatment as usual
- 67.9% responded with VNS Therapy

“We are **very encouraged** by the results of this unprecedented study, and hope that VNS becomes more readily available as a viable option for patients who have been through countless interventions for severe, chronic depression.”

- *Dr. Scott Aaronson, lead investigator, Sheppard Pratt Health System*

Sources: Aaronson et al. American Journal of Psychiatry. 2017; 174(7): 640-48.; WHO Depression Fact sheet: <http://www.who.int/mediacentre/factsheets/fs369/en/>; RC Kessler and EJ Bromet. Annu Rev Public Health. 2013; 34:119–138.; Rush et al. Am J Psychiatry 2006; 163:1905–1917.; Rush et al. Psychiatric Annals. 2008; 38(3):188-193.; Gaynes et al. AHRQ Publication No. 11-EHC056-EF. September 2011.

Exploring options for LivaNova's TRD treatment

Received CE Mark in 2001

Received FDA approval in 2005

Currently have 4,000 devices implanted over ~18-month period

Started pilot trial in Germany in 1Q17

Planning scaled launch in other European countries where we have approval and reimbursement

Ongoing discussions with CMS to gain U.S. reimbursement approval

Summary: a pioneer in Neuromodulation with robust growth opportunities

Epilepsy

- Strong core growth driven by consistent product innovation
- Label expansion increases patient pool
- International expansion opportunities
- Inorganic opportunities drive high-single- to low-double-digit growth trajectory

Depression

- Massive market opportunity with unmet need
- 800+ TRD patients show positive results with VNS Therapy
- Piloting in selected European countries
- In discussions with CMS on reconsideration and coverage with evidence development in the U.S.

Future Technology Enhancements

- Universal platform
- Enhanced diagnostic capabilities
- Wireless
- Wearables
- Patient/physician apps
- Improved data and analytics

LivaNova

Health innovation that matters